drugset / Trial / NCT05259189
A Study of NBL-012 in Healthy Chinese Subjects
RandomizedSequentialDouble-blindTreatment
Summary
This is a phase 1, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the safety, tolerability and pharmacokinetics (PK) of NBL-012 as single ascending doses (SAD) administered subcutaneously to healthy Chinese subjects.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2022-05-23
- Completion
- 2022-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBL-012 | Unknown | — | Subcutaneous |
Indications
No indication recorded.